TipRanks
AstraZeneca PLC (MX:AZN1N)
:AZN1N
Mexico Market
AZN1N
AstraZeneca
RESEARCH TOOLSreports

AstraZeneca (AZN1N) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

AZN1N Analyst Ratings

Strong Buy
17Ratings
Strong Buy
15 Buy
2 Hold
0 Sell
Based on 17 analysts giving stock ratings to
AstraZeneca
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

AZN1N Stock 12 Month Forecast

Average Price Target

$3,857.45
▲(41.95% Upside)
Based on 17 Wall Street analysts offering 12 month price targets for AstraZeneca in the last 3 months. The average price target is $3,857.45 with a high forecast of $4,878.80 and a low forecast of $2,824.65. The average price target represents a 41.95% change from the last price of $2,717.48.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2709":"$2,709","3794":"$3,794","4879":"$4,879","3251.5":"$3,251.5","4336.5":"$4,336.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":4878.79591,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$4.88K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3857.44562705375,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$3.86K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2824.65416142,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$2.82K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2709,3251.5,3794,4336.5,4879],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2964,3111.291993076923,3258.583986153846,3405.875979230769,3553.1679723076923,3700.4599653846153,3847.7519584615384,3995.0439515384614,4142.3359446153845,4289.627937692308,4436.919930769231,4584.211923846154,4731.503916923077,{"y":4878.79591,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2964,3032.726586696442,3101.4531733928848,3170.179760089327,3238.906346785769,3307.6329334822112,3376.359520178654,3445.086106875096,3513.812693571538,3582.5392802679808,3651.265866964423,3719.992453660865,3788.7190403573077,{"y":3857.44562705375,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2964,2953.28108934,2942.56217868,2931.84326802,2921.12435736,2910.4054467,2899.68653604,2888.96762538,2878.24871472,2867.52980406,2856.8108934,2846.09198274,2835.37307208,{"y":2824.65416142,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2710.424,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2710.424,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3313.734,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3232.841,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3176.982,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3498.903,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3259.439,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3288.228,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3145.175,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3242.183,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 57,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 10</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2942.517,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 64,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 10</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2717.48,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 72,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2964,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$4,879Average Price Target$3,857Lowest Price Target$2,825
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Barclays Analyst forecast on MX:AZN1N
James Gordon CFA
Barclays
Barclays
$3,862.77
Buy
42.15%
Upside
Reiterated
10/01/26
Barclays Keeps Their Buy Rating on AstraZeneca (AZN)
RBC Capital Analyst forecast on MX:AZN1N
Trung Huynh
RBC Capital
RBC Capital
$3,500.64
Buy
28.82%
Upside
Reiterated
09/29/26
RBC Capital Reaffirms Their Buy Rating on AstraZeneca (AZN)
Bernstein Analyst forecast on MX:AZN1N
Justin Smith
Bernstein
Bernstein
$4,878.8
Buy
79.53%
Upside
Reiterated
09/29/26
Bernstein Remains a Buy on AstraZeneca (AZN)
Deutsche Bank Analyst forecast on MX:AZN1N
Emmanuel Papadakis
Deutsche Bank
Deutsche Bank
$2,824.65
Hold
3.94%
Upside
Reiterated
09/29/26
Deutsche Bank Keeps Their Hold Rating on AstraZeneca (AZN)
J.P. Morgan Analyst forecast on MX:AZN1N
Richard Vosser
J.P. Morgan
J.P. Morgan
$3,864.39
Buy
42.21%
Upside
Reiterated
09/29/26
J.P. Morgan Sticks to Their Buy Rating for AstraZeneca (AZN)
Goldman Sachs Analyst forecast on MX:AZN1N
Rajan Sharma
Goldman Sachs
Goldman Sachs
$4,006.51
Buy
47.43%
Upside
Reiterated
09/29/26
AstraZeneca Secures $2 Billion Summit Therapeutics Oncology Partnership, Bolstering GI Cancer Pipeline and Supporting Buy Rating on AZN
Bank of America Securities Analyst forecast on MX:AZN1N
Sachin Jain
Bank of America Securities
Bank of America Securities
$3,985.16
Buy
46.65%
Upside
Reiterated
09/29/26
AstraZeneca’s Summit Partnership Bolsters Oncology Strategy; Buy Rating Reiterated with Unchanged 16,500 GBp Price Target
Citi Analyst forecast on MX:AZN1N
Graham Parry
Citi
Citi
$4,297.34
Buy
58.14%
Upside
Reiterated
09/29/26
AstraZeneca’s Oncology Strategy and Summit Deal Reinforce Growth Outlook; Buy Rating and $178 Price Target Reiterated
Jefferies Analyst forecast on MX:AZN1N
Michael Leuchten
Jefferies
Jefferies
$4,224.91
Buy
55.47%
Upside
Reiterated
09/29/26
AstraZeneca (AZN) Receives a Buy from Jefferies
UBS Analyst forecast on MX:AZN1N
Colin White
UBS
UBS
$3,671.17
Buy
35.09%
Upside
Reiterated
09/16/26
UBS Sticks to Their Buy Rating for AstraZeneca (AZN)
Berenberg Bank Analyst forecast on MX:AZN1N
Luisa Hector
Berenberg Bank
Berenberg Bank
$3,862.77→$3,621.35
Buy
33.26%
Upside
Reiterated
09/14/26
Berenberg Bank Remains a Buy on AstraZeneca (AZN)
HSBC Analyst forecast on MX:AZN1N
Rajesh Kumar
HSBC
HSBC
$3,320.96→$3,362.02
Hold
23.72%
Upside
Reiterated
09/10/26
AstraZeneca price target raised to 13,920 GBp from 13,750 GBp at HSBCAstraZeneca price target raised to 13,920 GBp from 13,750 GBp at HSBC
TD Cowen Analyst forecast on MX:AZN1N
Steve Scala
TD Cowen
TD Cowen
$4,390.7
Buy
61.57%
Upside
Reiterated
08/31/26
Steve Scala Reiterates Buy on AstraZeneca Citing Above-Peer EPS Growth Outlook and Selective Pipeline Upside
CICC Analyst forecast on MX:AZN1N
Unknown Analyst
CICC
Not Ranked
CICC
$3,622.33
Buy
33.30%
Upside
Initiated
08/24/26
AstraZeneca initiated with an Outperform at CICCAstraZeneca initiated with an Outperform at CICC
DZ BANK AG Analyst forecast on MX:AZN1N
Elmar Kraus
DZ BANK AG
DZ BANK AG
―
Buy
―
Reiterated
07/28/26
DZ BANK AG Sticks to Their Buy Rating for AstraZeneca (AZN)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Barclays Analyst forecast on MX:AZN1N
James Gordon CFA
Barclays
Barclays
$3,862.77
Buy
42.15%
Upside
Reiterated
10/01/26
Barclays Keeps Their Buy Rating on AstraZeneca (AZN)
RBC Capital Analyst forecast on MX:AZN1N
Trung Huynh
RBC Capital
RBC Capital
$3,500.64
Buy
28.82%
Upside
Reiterated
09/29/26
RBC Capital Reaffirms Their Buy Rating on AstraZeneca (AZN)
Bernstein Analyst forecast on MX:AZN1N
Justin Smith
Bernstein
Bernstein
$4,878.8
Buy
79.53%
Upside
Reiterated
09/29/26
Bernstein Remains a Buy on AstraZeneca (AZN)
Deutsche Bank Analyst forecast on MX:AZN1N
Emmanuel Papadakis
Deutsche Bank
Deutsche Bank
$2,824.65
Hold
3.94%
Upside
Reiterated
09/29/26
Deutsche Bank Keeps Their Hold Rating on AstraZeneca (AZN)
J.P. Morgan Analyst forecast on MX:AZN1N
Richard Vosser
J.P. Morgan
J.P. Morgan
$3,864.39
Buy
42.21%
Upside
Reiterated
09/29/26
J.P. Morgan Sticks to Their Buy Rating for AstraZeneca (AZN)
Goldman Sachs Analyst forecast on MX:AZN1N
Rajan Sharma
Goldman Sachs
Goldman Sachs
$4,006.51
Buy
47.43%
Upside
Reiterated
09/29/26
AstraZeneca Secures $2 Billion Summit Therapeutics Oncology Partnership, Bolstering GI Cancer Pipeline and Supporting Buy Rating on AZN
Bank of America Securities Analyst forecast on MX:AZN1N
Sachin Jain
Bank of America Securities
Bank of America Securities
$3,985.16
Buy
46.65%
Upside
Reiterated
09/29/26
AstraZeneca’s Summit Partnership Bolsters Oncology Strategy; Buy Rating Reiterated with Unchanged 16,500 GBp Price Target
Citi Analyst forecast on MX:AZN1N
Graham Parry
Citi
Citi
$4,297.34
Buy
58.14%
Upside
Reiterated
09/29/26
AstraZeneca’s Oncology Strategy and Summit Deal Reinforce Growth Outlook; Buy Rating and $178 Price Target Reiterated
Jefferies Analyst forecast on MX:AZN1N
Michael Leuchten
Jefferies
Jefferies
$4,224.91
Buy
55.47%
Upside
Reiterated
09/29/26
AstraZeneca (AZN) Receives a Buy from Jefferies
UBS Analyst forecast on MX:AZN1N
Colin White
UBS
UBS
$3,671.17
Buy
35.09%
Upside
Reiterated
09/16/26
UBS Sticks to Their Buy Rating for AstraZeneca (AZN)
Berenberg Bank Analyst forecast on MX:AZN1N
Luisa Hector
Berenberg Bank
Berenberg Bank
$3,862.77→$3,621.35
Buy
33.26%
Upside
Reiterated
09/14/26
Berenberg Bank Remains a Buy on AstraZeneca (AZN)
HSBC Analyst forecast on MX:AZN1N
Rajesh Kumar
HSBC
HSBC
$3,320.96→$3,362.02
Hold
23.72%
Upside
Reiterated
09/10/26
AstraZeneca price target raised to 13,920 GBp from 13,750 GBp at HSBCAstraZeneca price target raised to 13,920 GBp from 13,750 GBp at HSBC
TD Cowen Analyst forecast on MX:AZN1N
Steve Scala
TD Cowen
TD Cowen
$4,390.7
Buy
61.57%
Upside
Reiterated
08/31/26
Steve Scala Reiterates Buy on AstraZeneca Citing Above-Peer EPS Growth Outlook and Selective Pipeline Upside
CICC Analyst forecast on MX:AZN1N
Unknown Analyst
CICC
Not Ranked
CICC
$3,622.33
Buy
33.30%
Upside
Initiated
08/24/26
AstraZeneca initiated with an Outperform at CICCAstraZeneca initiated with an Outperform at CICC
DZ BANK AG Analyst forecast on MX:AZN1N
Elmar Kraus
DZ BANK AG
DZ BANK AG
―
Buy
―
Reiterated
07/28/26
DZ BANK AG Sticks to Their Buy Rating for AstraZeneca (AZN)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
ONCBeOne Medicines
OVIDOvid Therapeutics
WSTWest Pharmaceutical Services
ZYMEZymeworks
SLDBSolid Biosciences
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering AstraZeneca

3 Months
Luisa HectorBerenberg Bank
Success Rate
31/52 ratings generated profit
60%
Average Return
+2.69%
Copying Luisa Hector's trades and holding each position for 3 Months would result in 59.62% of your transactions generating a profit, with an average return of +2.69% per trade.
1 Year
Luisa HectorBerenberg Bank
Success Rate
37/52 ratings generated profit
71%
Average Return
+10.84%
Copying Luisa Hector's trades and holding each position for 1 Year would result in 71.15% of your transactions generating a profit, with an average return of +10.84% per trade.
2 Years
Luisa HectorBerenberg Bank
Success Rate
42/52 ratings generated profit
81%
Average Return
+18.78%
Copying Luisa Hector's trades and holding each position for 2 Years would result in 80.77% of your transactions generating a profit, with an average return of +18.78% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

AZN1N Analyst Recommendation Trends

Rating
Jun 26
Jul 26
Aug 26
Sep 26
Oct 26
Strong Buy
0
1
4
6
5
Buy
43
56
60
66
37
Hold
1
1
1
4
3
Sell
8
10
10
8
5
Strong Sell
0
0
0
0
0
total
52
68
75
84
50
In the current month, AZN1N has received 42 Buy Ratings, 3 Hold Ratings, and 5 Sell Ratings. AZN1N average Analyst price target in the past 3 months is 3,857.45.
Each month's total comprises the sum of three months' worth of ratings.

AZN1N Financial Forecast

AZN1N Earnings Forecast

Next quarter’s earnings estimate for AZN1N is $48.04 with a range of $45.00 to $53.05. The previous quarter’s EPS was $48.11. AZN1N beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year AZN1N has Performed in-line its overall industry.
Next quarter’s earnings estimate for AZN1N is $48.04 with a range of $45.00 to $53.05. The previous quarter’s EPS was $48.11. AZN1N beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year AZN1N has Performed in-line its overall industry.

AZN1N Sales Forecast

Next quarter’s sales forecast for AZN1N is $293.91B with a range of $288.60B to $298.55B. The previous quarter’s sales results were $276.70B. AZN1N beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year AZN1N has Performed in-line its overall industry.
Next quarter’s sales forecast for AZN1N is $293.91B with a range of $288.60B to $298.55B. The previous quarter’s sales results were $276.70B. AZN1N beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year AZN1N has Performed in-line its overall industry.

AZN1N Stock Forecast FAQ

What is MX:AZN1N’s average 12-month price target, according to analysts?
Based on analyst ratings, AstraZeneca PLC’s 12-month average price target is 3,857.45.
    What is MX:AZN1N’s upside potential, based on the analysts’ average price target?
    AstraZeneca PLC has 41.95% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is AstraZeneca PLC a Buy, Sell or Hold?
          AstraZeneca PLC has a consensus rating of Strong Buy, which is based on 15 buy ratings, 2 hold ratings and 0 sell ratings.
            What is AstraZeneca PLC’s share price target?
            The average share price target for AstraZeneca PLC is 3,857.45. This is based on 17 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is $4,878.80 ,and the lowest forecast is $2,824.65. The average share price target represents 41.95% Increase from the current price of $2,717.48.
              What do analysts say about AstraZeneca PLC?
              AstraZeneca PLC’s analyst rating consensus is a Strong Buy. This is based on the ratings of 17 Wall Streets Analysts.
                How can I buy shares of AstraZeneca PLC?
                To buy shares of MX:AZN1N, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.